应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
IND Xtrackers Nifty 500 India ETF
盘后交易 01-13 18:05:26 EST
24.31
-0.28
-1.14%
最高
24.31
最低
24.27
成交量
519.00
今开
24.27
昨收
24.59
日振幅
0.16%
总市值
486.20万
流通市值
486.20万
总股本
20.00万
成交额
1.26万
换手率
0.26%
流通股本
20.00万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
这家药企又一款新药临床申请获FDA许可,国际化发展持续加速
制药网 · 01-08
这家药企又一款新药临床申请获FDA许可,国际化发展持续加速
港股异动 | 康宁杰瑞制药-B(09966)涨超6% 近日SKN033的一项II期临床试验IND申请获受理
智通财经 · 01-08
港股异动 | 康宁杰瑞制药-B(09966)涨超6% 近日SKN033的一项II期临床试验IND申请获受理
康希诺:2025年公司4款候选产品已获得批准IND/NDA
证券日报 · 01-06
康希诺:2025年公司4款候选产品已获得批准IND/NDA
港股异动 | 复宏汉霖(02696)现涨近9% 公司旗下三款实体瘤创新药IND同期获受理
智通财经 · 01-05
港股异动 | 复宏汉霖(02696)现涨近9% 公司旗下三款实体瘤创新药IND同期获受理
歌礼制药-B(01672)宣布ASC30在糖尿病受试者中的 13周II期研究IND获美国FDA批准
智通财经 · 01-05
歌礼制药-B(01672)宣布ASC30在糖尿病受试者中的 13周II期研究IND获美国FDA批准
海思科(002653.SZ):“HSK50042”、“HSK55879”创新药IND申请获受理
智通财经 · 2025-12-30
海思科(002653.SZ):“HSK50042”、“HSK55879”创新药IND申请获受理
康宁杰瑞制药-B(09966):JSKN033的一项II期临床试验的IND申请获CDE正式受理
智通财经 · 2025-12-29
康宁杰瑞制药-B(09966):JSKN033的一项II期临床试验的IND申请获CDE正式受理
友芝友生物-B(02496):Y225(艾美赛珠单抗注射液)取得NMPA的IND批准
智通财经 · 2025-12-24
友芝友生物-B(02496):Y225(艾美赛珠单抗注射液)取得NMPA的IND批准
和誉-B(02256):口服小分子KRAS G12D抑制剂ABSK141的IND获NMPA批准
智通财经 · 2025-12-24
和誉-B(02256):口服小分子KRAS G12D抑制剂ABSK141的IND获NMPA批准
海思科(002653.SZ)获得创新药HSK46575片新增适应症IND申请受理
智通财经 · 2025-12-22
海思科(002653.SZ)获得创新药HSK46575片新增适应症IND申请受理
康宁杰瑞制药-B(09966):JSKN027 IND申请获CDE正式受理
智通财经 · 2025-12-17
康宁杰瑞制药-B(09966):JSKN027 IND申请获CDE正式受理
港股异动 | 百奥赛图-B(02315)涨超3% 授权IDEAYA双抗ADC项目IDE034获FDA IND批准
智通财经 · 2025-12-05
港股异动 | 百奥赛图-B(02315)涨超3% 授权IDEAYA双抗ADC项目IDE034获FDA IND批准
百奥赛图-B(02315)业务合作伙伴IDEAYA取得美国食品药品监督管理局对IDE034的IND批准
智通财经 · 2025-12-05
百奥赛图-B(02315)业务合作伙伴IDEAYA取得美国食品药品监督管理局对IDE034的IND批准
德琪医药-B(06996):ATG-022联合KEYTRUDA®(帕博利珠单抗)±化疗的IB/II期研究于中国获授予IND批准
智通财经 · 2025-12-02
德琪医药-B(06996):ATG-022联合KEYTRUDA®(帕博利珠单抗)±化疗的IB/II期研究于中国获授予IND批准
和誉-B(02256):口服小分子KRAS G12D抑制剂 ABSK141的IND申请获FDA批准
智通财经 · 2025-12-01
和誉-B(02256):口服小分子KRAS G12D抑制剂 ABSK141的IND申请获FDA批准
维立志博-B(09887):LBL-047取得NMPA的IND批准
智通财经 · 2025-12-01
维立志博-B(09887):LBL-047取得NMPA的IND批准
加载更多
公司概况
公司名称:
Xtrackers Nifty 500 India ETF
所属市场:
NASDAQ
上市日期:
--
主营业务:
荷兰国际集团是在1991年由荷兰国民人寿保险公司和荷兰邮政银行集团合并组成的综合性财政金融集团。据美国财富(FORTUNES)杂志统计,以资产净值计算,荷兰国际集团位居全球500家大企业的第64位。在提供综合性金融财经业务方面(银行与保险业务),居世界第三位。目前,该集团在世界上65个国家和地区设有分支机构,雇员超过10万人。2000年,该集团取得税后净利润49亿欧元,同比增长24%。截至2000年底,集团资产总额达5030亿欧元。 管理结构: 在董事会下面设有四个管理运作核心,荷兰总部;国际金融财经业务部;企业和资本市场部;资产管理部。 集团总部:负责荷兰本国市场上的全部保险和银行业务。 国际金融财经业务部:所有荷兰本土以外的国际保险业、零售银行业和商业银行业的运作皆由该中心管理。其保险业务划分三大地区:欧洲和拉丁美洲、北美洲、亚澳地区。银行业务则由中心统一管理。 企业及资本市场部:所有国际货币和资本市场管理部门都由该部门管理。包括国际银行网络以及金融产品、贸易、销售、投资银行、企业银行、风险管理及调研的各项业务。 资产管理部:该部门承担企业投资者的资产和帐目管理、提供个人国际银行服务以及集团公司的保险业务的资产管理。房地产业务和信托业务也属于这个部门管理。该部门同时管理荷兰国际集团各个公司的投资基金。
发行价格:
--
{"stockData":{"symbol":"IND","market":"US","secType":"STK","nameCN":"Xtrackers Nifty 500 India ETF","latestPrice":24.31,"timestamp":1768338000000,"preClose":24.59,"halted":0,"volume":519,"delay":0,"floatShares":200001,"shares":200001,"eps":0,"marketStatus":"盘后交易","change":-0.28,"latestTime":"01-13 18:05:26 EST","open":24.27,"high":24.31,"low":24.27,"amount":12610.756977,"amplitude":0.001627,"askPrice":36.6,"askSize":200,"bidPrice":12.2,"bidSize":200,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1768352400000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":24.59,"sharesOutstanding":200001,"nav":24.387,"aum":4877368.7,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":24.44,"preClose":24.59,"latestTime":"09:29 EST","volume":42,"amount":1026.48,"timestamp":1768314591924},"volumeRatio":0.320648},"requestUrl":"/m/hq/s/IND","defaultTab":"news","newsList":[{"id":"2602347075","title":"这家药企又一款新药临床申请获FDA许可,国际化发展持续加速","url":"https://stock-news.laohu8.com/highlight/detail?id=2602347075","media":"制药网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602347075?lang=zh_cn&edition=full","pubTime":"2026-01-08 15:42","pubTimestamp":1767858161,"startTime":"0","endTime":"0","summary":"近日,亚盛医药宣布BTK降解剂APG-3288的新药临床申请获美国FDA许可,将开展其治疗复发/难治B细胞恶性肿瘤的临床研究。截至目前,公司已共有4个在研新药获得16项FDA和1项欧盟孤儿药资格认定,2项FDA快速通道资格以及2项FDA儿童罕见病资格认证。业内预计,随着亚盛医药重磅品种临床的持续推进,以及与跨国药企及顶尖学术机构的深度合作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108160110a4ab1664&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108160110a4ab1664&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IND","ASPHF","BK4139"],"gpt_icon":0},{"id":"2601336363","title":"港股异动 | 康宁杰瑞制药-B(09966)涨超6% 近日SKN033的一项II期临床试验IND申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2601336363","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601336363?lang=zh_cn&edition=full","pubTime":"2026-01-08 10:10","pubTimestamp":1767838222,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,康宁杰瑞制药-B涨超6%,截至发稿,涨6.76%,报10.89港元,成交额1041.75万港元。消息面上,近日,康宁杰瑞制药-B发布公告,JSKN033联合铂类化疗联合或不联合贝伐珠单抗一线治疗晚期宫颈癌的一项II期临床试验的新药临床试验申请,已获国家药品监督管理局药品审评中心正式受理。所有患者将接受JSKN033联合顺铂或卡铂联合或不联合贝伐珠单抗的治疗。铂类药物的选择和是否联用贝伐珠单抗将由研究者根据患者的具体情况决定。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390200.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","IND","09966","BK1161"],"gpt_icon":0},{"id":"2601890033","title":"康希诺:2025年公司4款候选产品已获得批准IND/NDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2601890033","media":"证券日报 ","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601890033?lang=zh_cn&edition=full","pubTime":"2026-01-06 21:32","pubTimestamp":1767706320,"startTime":"0","endTime":"0","summary":"产品获批及研发端,2025年公司4款候选产品已获得批准IND/NDA,以及启动2个新的临床试验,以2026年设置的业绩考核目标A档来看,2026年至少包括5款候选产品获得批准IND、获得批准NDA,以及至少启动2个新的临床试验。目前也是在按既定的研发节奏推进,公司也会和药监、中检院及临床试验合作方等积极沟通,以期顺利推进相应候选产品的研发里程碑。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-06/doc-inhfkskh5784664.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-06/doc-inhfkskh5784664.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IND","688185","BK0239"],"gpt_icon":0},{"id":"2601071879","title":"港股异动 | 复宏汉霖(02696)现涨近9% 公司旗下三款实体瘤创新药IND同期获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2601071879","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601071879?lang=zh_cn&edition=full","pubTime":"2026-01-05 11:02","pubTimestamp":1767582152,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,复宏汉霖(02696)现涨近9%,截至发稿,涨8.62%,报63.65港元,成交额2904.28万港元。消息面上,12月30日,复宏汉霖宣布,公司三款潜力创新分子——基于自研T细胞衔接器(TCE)平台开发的DLL3xDLL3xCD3xCD28四特异性TCE HLX3901、潜在同类最优(BIC)的新型KAT6A/B口服小分子抑制剂HLX97、以及潜在同类首创(FIC)的B7H3-唾液酸酶融合蛋白HLX316的新药临床试验申请均已获得国家药品监督管理局受理。以上三款产品皆拟用于实体肿瘤的治疗。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1388498.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","02696","IND","HK0000165453.HKD","159992","06978"],"gpt_icon":0},{"id":"2601785620","title":"歌礼制药-B(01672)宣布ASC30在糖尿病受试者中的 13周II期研究IND获美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2601785620","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601785620?lang=zh_cn&edition=full","pubTime":"2026-01-05 08:13","pubTimestamp":1767572009,"startTime":"0","endTime":"0","summary":"智通财经APP讯,歌礼制药-B 公布,近期已获得美国食品药品监督管理局 对其口服小分子GLP-1,ASC30,在糖尿病受试者中的II期研究的新药临床试验的批准。该II期研究是一项为期13周、随机、双盲、安慰剂对照及多中心的研究,旨在评估ASC30在2型糖尿病受试者中的疗效、安全性和耐受性。歌礼已于近期完成其评估口服小分子GLP-1受体激动剂ASC30治疗肥胖症的13周II期研究。在ASC30用于治疗肥胖或超重的II期研究中,因不良事件导致的总体停药率为4.8%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f1a65319f224684be7c4d1ad3324a2f2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1388409.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IND","BK1574","01477","01672","BK1515","BK1191","BK1161"],"gpt_icon":0},{"id":"2595670427","title":"海思科(002653.SZ):“HSK50042”、“HSK55879”创新药IND申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2595670427","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595670427?lang=zh_cn&edition=full","pubTime":"2025-12-30 16:20","pubTimestamp":1767082829,"startTime":"0","endTime":"0","summary":"智通财经APP讯,海思科 发布公告,公司子公司上海海思盛诺医药科技有限公司于近日收到国家药品监督管理局下发的《受理通知书》,涉及产品:“HSK50042”、“HSK55879”。本次申请为HSK50042片在呼吸系统疾病领域中又一新适应症的临床试验申请,有望为呼吸疾病患者提供一种高效、安全的新型治疗选择。HSK55879片是公司自主研发的具有独立知识产权的口服小分子激动剂药物,拟用于代谢系统疾病的治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1387080.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0033","002653","BK0239","BK1574","IND","BK0028","BK0077","06978","159992","BK0188","BK1161"],"gpt_icon":0},{"id":"2595040206","title":"康宁杰瑞制药-B(09966):JSKN033的一项II期临床试验的IND申请获CDE正式受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2595040206","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595040206?lang=zh_cn&edition=full","pubTime":"2025-12-29 12:17","pubTimestamp":1766981869,"startTime":"0","endTime":"0","summary":"智通财经APP讯,康宁杰瑞制药-B 发布公告,JSKN033联合铂类化疗联合或不联合贝伐珠单抗一线治疗晚期宫颈癌的一项II期临床试验的新药临床试验申请,已获国家药品监督管理局药品审评中心正式受理。所有患者将接受JSKN033联合顺铂或卡铂联合或不联合贝伐珠单抗的治疗。铂类药物的选择和是否联用贝伐珠单抗将由研究者根据患者的具体情况决定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1386406.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","LU1223082519.USD","LU1223083913.SGD","BK4017","LU1223082196.USD","09966","IND","CDE"],"gpt_icon":0},{"id":"2593471543","title":"友芝友生物-B(02496):Y225(艾美赛珠单抗注射液)取得NMPA的IND批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2593471543","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593471543?lang=zh_cn&edition=full","pubTime":"2025-12-24 19:37","pubTimestamp":1766576227,"startTime":"0","endTime":"0","summary":"智通财经APP讯,友芝友生物-B 发布公告,于2025年12月23日,其生物类似药Y225的临床试验申请已获中华人民共和国国家药品监督管理局批准。Y225是一种用于治疗A型血友病的双特异性抗体舒友立乐生物类似药。本次获批的临床试验是一项在健康成年人中进行的随机、双盲、单剂量、平行比较舒友立乐与Y225在健康男性受试者中的生物等效性临床研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385601.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02496","IND","BK1161"],"gpt_icon":0},{"id":"2593418484","title":"和誉-B(02256):口服小分子KRAS G12D抑制剂ABSK141的IND获NMPA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2593418484","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593418484?lang=zh_cn&edition=full","pubTime":"2025-12-24 08:02","pubTimestamp":1766534531,"startTime":"0","endTime":"0","summary":"智通财经APP讯,和誉-B(02256)发布公告,公司的附属公司上海和誉生物医药科技有限公司(和誉医药)宣布,其口服、高活性、高选择性小分子KRAS G12D抑制剂ABSK141用于治疗携带KRAS G12D突变的晚期实体瘤患者的新药临床试验(IND)申请已获中国国家药品监督管理局(NMPA)批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385238.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02256","IE00B543WZ88.USD","LU2476274308.USD","LU2778985437.USD","IE00B5MMRT66.SGD","LU2476274720.SGD","IE00BPRC5H50.USD","IND","BK1161","LU2488822045.USD"],"gpt_icon":0},{"id":"2593485369","title":"海思科(002653.SZ)获得创新药HSK46575片新增适应症IND申请受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2593485369","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593485369?lang=zh_cn&edition=full","pubTime":"2025-12-22 17:36","pubTimestamp":1766396197,"startTime":"0","endTime":"0","summary":"智通财经APP讯,海思科 发布公告,公司子公司辽宁海思科制药有限公司于近日收到国家药品监督管理局下发的《受理通书》,涉及药品:“HSK46575”。本次获得受理的为本品联合奥拉帕利片或联合多西他赛和泼尼松片用于前列腺癌的治疗适应症的临床试验申请。HSK46575片是公司自主研发的一种口服、强效和高选择性的小分子抑制剂,拟用于前列腺癌的治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384452.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0077","BK1161","002653","BK1574","BK0188","159992","BK0033","BK0028","BK0239","IND","06978"],"gpt_icon":0},{"id":"2592399645","title":"康宁杰瑞制药-B(09966):JSKN027 IND申请获CDE正式受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2592399645","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592399645?lang=zh_cn&edition=full","pubTime":"2025-12-17 18:08","pubTimestamp":1765966104,"startTime":"0","endTime":"0","summary":"智通财经APP讯,康宁杰瑞制药-B 发布公告,公司自主研发的程序性死亡配体1/血管内皮生长因子受体2双特异性抗体偶联药物JSKN027新药临床试验申请,已获国家药品监督管理局药品审评中心正式受理。JSKN027是全球首款进入临床研究阶段的PD-L1/VEGFR2双抗ADC药物。临床前数据显示,JSKN027在体外及体内模型中均表现出显著的肿瘤抑制活性。基于其细胞毒杀伤、抗血管生成及免疫调节等多重作用机制,JSKN027有望为多种实体瘤治疗提供新的治疗选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1382657.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4017","IND","LU1223082519.USD","LU1223082196.USD","CDE","09966","LU1223083913.SGD","BK1574"],"gpt_icon":0},{"id":"2589448869","title":"港股异动 | 百奥赛图-B(02315)涨超3% 授权IDEAYA双抗ADC项目IDE034获FDA IND批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2589448869","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589448869?lang=zh_cn&edition=full","pubTime":"2025-12-05 14:46","pubTimestamp":1764917191,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,百奥赛图-B涨超3%,截至发稿,涨2.84%,报31.86港元,成交1299.1万港元。IDEAYA预计将在2026年第一季度开始患者入组,初步评估B7H3和PTK7共表达的实体瘤类型,包括肺癌、结直肠癌、头颈癌及卵巢/妇科肿瘤。此外,IDEAYA计划探索IDE034与其PARG抑制剂IDE161的联合治疗策略,以增强疗效持续性,并计划在2026年上半年重要医学会议上分享更多支持PARG与TOP1 ADC联合治疗机制的数据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378080.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IND","02315","BK1161","BK4080","BK4231","ADC","688796"],"gpt_icon":0},{"id":"2589855702","title":"百奥赛图-B(02315)业务合作伙伴IDEAYA取得美国食品药品监督管理局对IDE034的IND批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2589855702","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589855702?lang=zh_cn&edition=full","pubTime":"2025-12-05 08:09","pubTimestamp":1764893379,"startTime":"0","endTime":"0","summary":"IDEAYA预计将在2026年第一季度开始患者入组,初步评估B7H3和PTK7共表达的实体瘤类型,包括肺癌、结直肠癌、头颈癌及卵巢╱ 妇科肿瘤。B7H3和PTK7在肺癌、结直肠癌及头颈癌等实体瘤中的共表达比例分别约为30%、46% 和27%,显示IDE034广泛的临床适应症潜力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377962.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688796","BK1161","02315","IND"],"gpt_icon":1},{"id":"2588035332","title":"德琪医药-B(06996):ATG-022联合KEYTRUDA®(帕博利珠单抗)±化疗的IB/II期研究于中国获授予IND批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2588035332","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588035332?lang=zh_cn&edition=full","pubTime":"2025-12-02 16:45","pubTimestamp":1764665132,"startTime":"0","endTime":"0","summary":"智通财经APP讯,德琪医药-B(06996)发布公告,中国国家药品监督管理局(国家药监局)已批准用于评估 ATG-022(CLDN18.2抗体药物偶联物ADC)联 合 MSD (Merck & Co., Inc., Rahway, NJ, USA)的抗PD 1疗法KEYTRUDA®(帕博利珠单抗)以及ATG-022联合帕博利珠单抗及化疗的Ib/II期CLINCH-2研究的研究性新药(IND)申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1376522.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1574","IND","06996","BK1583"],"gpt_icon":0},{"id":"2588210723","title":"和誉-B(02256):口服小分子KRAS G12D抑制剂 ABSK141的IND申请获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2588210723","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588210723?lang=zh_cn&edition=full","pubTime":"2025-12-01 17:40","pubTimestamp":1764582054,"startTime":"0","endTime":"0","summary":"智通财经APP讯,和誉-B(02256)发布公告,公司的附属公司上海和誉生物医药科技有限公司宣布,一种用于治疗携带KRAS G12D突变的晚期实体瘤患者的口服、高活性、高选择性小分子KRAS G12D抑制剂ABSK141的新药临床试验(IND)申请已获得美国食品药品监督管理局(FDA)批准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1376033.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02256","IE00B5MMRT66.SGD","LU2476274308.USD","IND","IE00BPRC5H50.USD","IE00B543WZ88.USD","LU2488822045.USD","LU2476274720.SGD","BK1161","LU2778985437.USD"],"gpt_icon":0},{"id":"2588382740","title":"维立志博-B(09887):LBL-047取得NMPA的IND批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2588382740","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588382740?lang=zh_cn&edition=full","pubTime":"2025-12-01 16:32","pubTimestamp":1764577967,"startTime":"0","endTime":"0","summary":"智通财经APP讯,维立志博-B 发布公告,于2025年11月25日,其自主研发候选药物LBL-047的新药临床试验申请已获中国国家药品监督管理局批准。目前全球范围内尚无同时靶向浆细胞样树突状细胞及B细胞的药物获批临床试验。LBL-047凭借此独特作用机制,具备同类第一及同类最优的潜力。其将评估LBL-047的安全性、耐受性及其在SLE患者中的初步临床有效性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1375951.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","HK0000500386.USD","HK0000252160.HKD","09887","IND","HK0000252152.HKD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ing.com","stockEarnings":[{"period":"1week","weight":-0.0219},{"period":"1month","weight":0.0062},{"period":"3month","weight":-0.0166},{"period":"ytd","weight":-0.0077}],"compareEarnings":[{"period":"1week","weight":0.0108},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.0497},{"period":"6month","weight":0.1136},{"period":"1year","weight":0.1975},{"period":"ytd","weight":0.0194}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"荷兰国际集团是在1991年由荷兰国民人寿保险公司和荷兰邮政银行集团合并组成的综合性财政金融集团。据美国财富(FORTUNES)杂志统计,以资产净值计算,荷兰国际集团位居全球500家大企业的第64位。在提供综合性金融财经业务方面(银行与保险业务),居世界第三位。目前,该集团在世界上65个国家和地区设有分支机构,雇员超过10万人。2000年,该集团取得税后净利润49亿欧元,同比增长24%。截至2000年底,集团资产总额达5030亿欧元。 管理结构: 在董事会下面设有四个管理运作核心,荷兰总部;国际金融财经业务部;企业和资本市场部;资产管理部。 集团总部:负责荷兰本国市场上的全部保险和银行业务。 国际金融财经业务部:所有荷兰本土以外的国际保险业、零售银行业和商业银行业的运作皆由该中心管理。其保险业务划分三大地区:欧洲和拉丁美洲、北美洲、亚澳地区。银行业务则由中心统一管理。 企业及资本市场部:所有国际货币和资本市场管理部门都由该部门管理。包括国际银行网络以及金融产品、贸易、销售、投资银行、企业银行、风险管理及调研的各项业务。 资产管理部:该部门承担企业投资者的资产和帐目管理、提供个人国际银行服务以及集团公司的保险业务的资产管理。房地产业务和信托业务也属于这个部门管理。该部门同时管理荷兰国际集团各个公司的投资基金。","yearOnYearQuotes":[{"month":1,"riseRate":0.857143,"avgChangeRate":0.027152},{"month":2,"riseRate":0.285714,"avgChangeRate":-0.031592},{"month":3,"riseRate":0.785714,"avgChangeRate":0.035422},{"month":4,"riseRate":0.571429,"avgChangeRate":0.017359},{"month":5,"riseRate":0.285714,"avgChangeRate":0.00595},{"month":6,"riseRate":0.714286,"avgChangeRate":0.006634},{"month":7,"riseRate":0.785714,"avgChangeRate":0.023298},{"month":8,"riseRate":0.4,"avgChangeRate":-0.016348},{"month":9,"riseRate":0.571429,"avgChangeRate":-0.024108},{"month":10,"riseRate":0.785714,"avgChangeRate":0.022259},{"month":11,"riseRate":0.357143,"avgChangeRate":-0.033495},{"month":12,"riseRate":0.642857,"avgChangeRate":0.020836}],"exchange":"NASDAQ","name":"Xtrackers Nifty 500 India ETF","nameEN":"Xtrackers Nifty 500 India ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Xtrackers Nifty 500 India ETF(IND)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Xtrackers Nifty 500 India ETF(IND)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Xtrackers Nifty 500 India ETF,IND,Xtrackers Nifty 500 India ETF股票,Xtrackers Nifty 500 India ETF股票老虎,Xtrackers Nifty 500 India ETF股票老虎国际,Xtrackers Nifty 500 India ETF行情,Xtrackers Nifty 500 India ETF股票行情,Xtrackers Nifty 500 India ETF股价,Xtrackers Nifty 500 India ETF股市,Xtrackers Nifty 500 India ETF股票价格,Xtrackers Nifty 500 India ETF股票交易,Xtrackers Nifty 500 India ETF股票购买,Xtrackers Nifty 500 India ETF股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Xtrackers Nifty 500 India ETF(IND)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Xtrackers Nifty 500 India ETF(IND)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}